Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: A randomized phase II study

Clinical Colorectal Cancer

Volumn 12, Issue 4, 2013, Pages 239-247

  Bendell, Johanna C ^a   Tournigand, Christophe ^b   Swieboda Sadlej, Anna ^c   Barone, Carlo ^d   Wainberg, Zev A ^e   Kim, Jong Gwang ^f   Pericay, Carles ^g   Pastorelli, Davide ^h   Tarazi, Jamal ⁱ   Rosbrook, Brad ⁱ   Bloom, Joanna ^j   Ricart, Alejandro D ⁱ   Kim, Sinil ⁱ   Sobrero, Alberto F ^k  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

^b HENRI MONDOR HOSPITAL   (France)

^c MEDICAL UNIVERSITY OF WARSAW   (Poland)

^d CATHOLIC UNIVERSITY   (Italy)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f Kyungpook National University School of Medicine   (South Korea)

^g Servicio de Oncología Médica   (Spain)

^h VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

ⁱ PFIZER INC   (United States)

^j Envision Pharma Group   (United States)

^k UNIVERSITY OF GENOA   (Italy)

more..

Author keywords

Chemotherapy; Irinotecan; Oxaliplatin; Second line; VEGF

Indexed keywords

AXITINIB; BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ABDOMINAL PAIN; ADULT; AGED; ALLERGIC REACTION; ALOPECIA; ANASTOMOSIS DEHISCENCE; ANEMIA; ARTICLE; ASTHENIA; BLEEDING; BRONCHITIS; CANCER COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ELEVATED BLOOD PRESSURE; EPISTAXIS; FATIGUE; FEMALE; HUMAN; HYPERTENSION; HYPOTHYROIDISM; INFUSION RELATED REACTION; INTESTINE PERFORATION; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MULTICENTER STUDY; NAUSEA; NEPHROTIC SYNDROME; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT DURATION; VOMITING;

CHEMOTHERAPY; IRINOTECAN; OXALIPLATIN; SECOND-LINE; VEGF;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; IMIDAZOLES; INDAZOLES; KAPLAN-MEIER ESTIMATE; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; ORGANOPLATINUM COMPOUNDS; YOUNG ADULT;

EID: 84887291388     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.1016/j.clcc.2013.09.001     Document Type: Article

References (22)

1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology™ Colon Cancer v.3. January 2012. Available at: http://www.nccn.org/index.asp. Accessed June 12, 2012.
2. C. Tournigand, T. André, and E. Achille FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study J Clin Oncol 22 2004 229 237
3. G.P. Hess, P.F. Wang, and D. Quach Systemic therapy for metastatic colorectal cancer: patterns of chemotherapy and biologic therapy use in US medical oncology practice J Oncol Pract 6 2010 301 307
4. H. Hurwitz, L. Fehrenbacher, and W. Novotny Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342
5. B.J. Giantonio, P.J. Catalano, and N.J. Meropol Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200 J Clin Oncol 25 2007 1539 1544
6. J. Bennouna, J. Sastre, and D. Arnold Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial Lancet Oncol 14 2013 29 37
7. E. Van Cutsem, J. Tabernero, and R. Lakomy Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen J Clin Oncol 30 2012 3499 3506
8. A. Grothey, E. Van Cutsem, and A. Sobrero Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial Lancet 381 2013 303 312
9. D.D. Hu-Lowe, H.Y. Zou, and M.L. Grazzini Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3 Clin Cancer Res 14 2008 7272 7283
10. E.E. Cohen, L.S. Rosen, and E.E. Vokes Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study J Clin Oncol 26 2008 4708 4713
11. J. Fruehauf, J. Lutzky, and D. McDermott Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma Clin Cancer Res 17 2011 7462 7469
12. B.I. Rini, G. Wilding, and G. Hudes Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma J Clin Oncol 27 2009 4462 4468
13. O. Rixe, R.M. Bukowski, and M.D. Michaelson Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study Lancet Oncol 8 2007 975 984
14. J.H. Schiller, T. Larson, and S.H. Ou Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study J Clin Oncol 27 2009 3836 3841
15. S. Sharma, V. Abhyankar, and R.E. Burgess A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors Ann Oncol 21 2010 297 304
16. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
17. A. Trotti, A.D. Colevas, and A. Setser CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment Semin Radiat Oncol 13 2003 176 181
18. J.R. Hecht, T. Trarbach, and J.D. Hainsworth Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma J Clin Oncol 29 2011 1997 2003
19. H.J. Schmoll, D. Cunningham, and A. Sobrero Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III) J Clin Oncol 30 2012 3588 3595
20. Hecht JR, Yoshino T, Mitchell EP, et al. A randomized, phase IIb study of sunitinib plus 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) versus bevacizumab plus mFOLFOX6 as first-line treatment for metastatic colorectal cancer (mCRC): interim results. Paper presented at: 46th Annual Meeting of the American Society of Clinical Oncology, June 4-8, 2010, Chicago, IL.
21. D. Cunningham, R.P. Wong, and G. D'Haens Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer Br J Cancer 108 2013 493 502
22. E. Van Cutsem, E. Bajetta, and J. Valle Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma J Clin Oncol 29 2011 2004 2010